Login to Your Account

Geography Could Be a Culprit

It's No Sugar Pill to Swallow: Placebo Effect Skewing Trials

By Randy Osborne

Monday, September 7, 2009
Last week's Phase III miss in Parkinson's disease psychosis by pimavanserin, the 5-HT2A inverse agonist from Acadia Pharmaceuticals Inc. and Biovail Corp., shone the spotlight once again on the "better-than-expected placebo effect," a persistent biotech bugaboo - a hazard that makes investors and scientists cringe.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription